Daily Medication Pearl: Ibrexafungerp (BREXAFEMME) for Vulvovaginal Candidiasis

Ibrexafungerp is a triterpenoid antifungal drug for adult and post-menarchal pediatric females with vulvovaginal candidiasis.

Medication Pearl of the Day: Ibrexafungerp (BREXAFEMME)

Indication: Ibrexafungerp is a triterpenoid antifungal indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis.

Insight:

  • Dosing: The recommended dosage of ibrexafungerp in adult and post-menarchal pediatric females is 300 mg (2 tablets of 150 mg) twice a day for 1 day, for a total treatment dosage of 600 mg.
  • Dosage form: Tablets 150 mg.
  • Adverse events (AEs): The most frequent AEs associated with this drug are diarrhea, nausea, abdominal pain, dizziness, and vomiting.
  • Mechanism of action: Ibrexafungerp is a triterpenoid antifungal drug.
  • Manufacturer: Scynexis

Sources: